Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
S-365598 aims to build on the success of dolutegravir & cabotegravir with potential to anchor the next-gen pipeline of HIV therapies
-
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Final FDA decision anticipated by 24 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEP
-
ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV
Paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic.
-
GSK to showcase significant scientific advances in renal care at the American Society of Nephrology Kidney Week 2021
Data from all five Phase 3 trials of the ASCEND programme for the investigational medicine daprodustat will be presented at the meeting.
-
Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040
The report offers actions to overcome the barriers that have blocked progress in achieving health equity across HIV, STIs, & COVID-19
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up
US CDC and Prevention’s Advisory Committee votes unanimously to recommend Shingrix for immunocompromised adults aged 19 & up
-
GSK delivers strong Q3 sales of £9.1 billion +5% AER, +10% CER Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS guidance improved
Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand
-
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings
The CARISEL study showed most people living with HIV who started treatment felt positive about the long-acting regimen
-
GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
Pivotal trials in non-dialysis and dialysis populations published simultaneously in the New England Journal of Medicine
-
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Phase III IM administration data for sotrovimab.
-
GSK showcases progress from the DREAMM clinical trial program in multiple myeloma at the 2021 ASH Annual Meeting
GlaxoSmithKline plc announces 11 abstracts on BLENREP will be presented at the upcoming ASH Annual Meeting and Exposition.
-
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide
-
GSK unveils Target the Future, a global, multi-year program to help address key challenges affecting the multiple myeloma community
$100,000 grant to be awarded to best idea submitted to Target the Future Think Tank Challenge
-
GSK Celebrates 25th IMPACT Awards, Boosting Investments Now Totaling $13M to Improve Health in RTP and Greater Philadelphia
20 nonprofits each receive $50,000 for work in mentoring, providing access to food, fighting homelessness and more
-
Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant
Data to be confirmed by further in vitro pseudo-virus testing
-
Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant
New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv
-
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants
-
New survey reveals majority of severe eosinophilic asthma patients and their physicians concerned about the current state of their health
New survey reveals majority of severe eosinophilic asthma patients and their physicians concerned about the current state of their health
-
New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment
GSK announced new data from the DREAMM-9 phase I trial and two GSK collaborative studies investigating the potential use of Blenrep.
-
GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of phase III trial per independent Monitoring Board recommendation
Companies intend to file booster data with regulatory authorities following the phase III results
